Entities

Venture Partner at Afore Capital

Managing Partner at Afore Capital

Founding General Partner at Eniac Ventures

Zal Bilimoria is the founder and solo General Partner of Refactor Capital, whose current own site identifies him as its sole employee. His first-person biography describes a decade in technology product, including YouTube monetization and Netflix’s first Head of Mobile, followed by joining Andreessen Horowitz in2013 and helping launch its first Bio Fund. He founded Refactor in2015, with public launch dated2016 in the firm’s2024 release, and backs seed-stage applied biology, health, energy, aerospace and other physical-world technology businesses. The2026 FundV filing identifies him as managing director of its general partner. His source-confirmed typical firm check range and reported AUM are not personal cash allocations. Original authentic portrait and existing personal Investor646/private fields/outside affiliations are preserved.

Alex Iskold is published by Techstars as MD Emeritus (alumni directory). This is an alumni/advisory directory affiliation and does not establish a current full-time managing-director appointment. The current published directory verifies the named affiliation; exact appointment dates are undisclosed.

Voima Ventures is a Nordic venture capital firm financing science-based companies and university spinouts across the Nordics and Baltics. Based in Helsinki and Stockholm, it invests from pre-seed through Series A and B in life sciences, medical technology, clean energy, advanced materials, quantum computing and AI. Its team combines investment experience with operating and research networks to help founders turn scientific discoveries into scalable businesses. Founded in 2019, the firm manages three funds; its Article 8 Fund III completed fundraising in 2024 and was reported at EUR 107 million in November 2025.

Sunfish Partners is an early-stage venture capital firm based in Berlin and Warsaw that backs deep-tech startups from Central and Eastern Europe. Its current investment focus is pre-seed space and defense businesses combining hardware and software. Its earlier and continuing portfolio also includes AI, digital health, neurological biomarkers, bionic prosthetics and computational drug discovery. The firm supports technical founders with initial capital and operational and sector expertise.

Team8 is a venture firm that both builds startups with founders and invests in existing early-stage companies across cybersecurity, software infrastructure, financial technology and digital health. Its venture creation model combines technical specialists, operators and market research to validate problems and develop new businesses. Its venture capital platform backs seed and Series A founders, including AI-native enterprise companies, and helps them test products with its network of enterprise executives, develop go-to-market plans and scale operations. Published team members, partners and external advisors have distinct roles in this model.

The Venture Collective (TVC) is a venture investment firm backing companies that use transformative technology and science to address major societal needs. Its public portfolio includes artificial intelligence, quantum computing, space infrastructure, biotechnology, brain health and other deep technology businesses, including BIOS Health, SPARK Neuro, Orbem, Universal Quantum, Life Biosciences and Axiom Space. Its current core team and advisers include founding partners Nicholas and Gina Shekerdemian, General Partner Cat Middleton, Partner Stephanie Sarelakos, Principal Chris Ghadban, Associates Ines Ullmo and Emily Aronin, CFO Pete Ondishin, Chairman Luke Lloyd-Davies, Executive in Residence Nicole Seligman, and Senior Advisors Elliot Richmond and Paula Sutter. TVC separately lists nine venture partners. The firm was a named investor in Caravel Bio's $1.9 million pre-seed financing announced in October 2025. Its public portfolio and track record include historical investments; current ownership, investment dates and individual funding amounts require company-level verification.

Quantitative trading and liquidity-provision firm with a venture investment business.

United Ventures is an independent Italian technology venture capital manager founded in 2013 by Paolo Gesess and Massimiliano Magrini. Its exact supervised legal manager is United Ventures SGR SpA, VAT IT08083670961, based at Piazza Fontana 1 in Milan; its own disclosure records Bank of Italy AIFM registration150 dated3March2016. It backs European technology companies from early stage through growth, including artificial intelligence, quantum technology, cybersecurity, cloud infrastructure, industrial IoT and computational life sciences. Current published investment involvement includes Aindo synthetic data, Algorithmiq quantum drug discovery, Exein embedded security and D-Orbit space infrastructure. Separate managed vehicles include United Ventures One SICAF EuVECA, UV2, UV2 Lazio, UV T-Growth, United Ventures III and United Ventures III Lombardia. Fund capital, interim commitments, regional allocations and fundraising targets are explicitly distinguished. The current published team has17 named people. Kyle O’Brien’s inherited managing-partner attribution conflicts with primary Unit Ventures identity and is preserved as a qualified legacy record pending separate financial attribution audit; Unit Ventures is a distinct manager.

Sarsia is a Bergen-based venture capital firm investing in early-stage, science-based companies in life sciences, technology, energy and environmental sustainability. It helps commercialize research addressing unmet medical needs and supports technologies that reduce environmental impact or improve resource efficiency. The firm typically invests NOK 2–5 million initially and can invest NOK 30–40 million in a company over successive financing rounds. Its team combines scientific expertise with commercial experience and works with portfolio companies on development plans, governance and fundraising, normally taking a board position. Sarsia Management AS manages the firm’s investment funds.

SciFounders is an early-stage venture investment firm helping technical founders build research-intensive companies from pre-seed through Series A. Its SciFounder Fellowship offers up to $1 million in initial support and hands-on mentorship; this is a potential company investment, not the firm's total fund size. The public team comprises Matt Krisiloff, Lucas Harrington and Alexander Schubert, with experience building Conception, Mammoth Biosciences and science-focused startups. Its portfolio spans genetic medicine, computational biology, mineral exploration and precision surgery, including Trace Biosciences, Luminate Medical, Current Surgical, Earth AI and Sculpta. Its FAQ welcomes software and hardware founders and describes equity investments rather than ownership of the inventors' patents. Historical NCI-hosted company material confirms a $400,000 SciFounders SAFE investment in Trace in 2021, and a January 2026 Luminate financing announcement names SciFounders among participants in an expanded $21 million Series A. Individual portfolio listings require further issuer-level checks for current status, business identity and financing details.

Skybound Venture Capital is a founder-led early-stage investment firm based in Athens, backing deep-technology companies from pre-seed and seed through follow-on rounds. It leads initial investments of EUR0.5–2 million and can provide up to EUR2 million in follow-on capital to selected portfolio companies. Its published areas include climate and energy technologies, agriculture, robotics, space, longevity and AI safety, with a broader focus on scientific and engineering innovations that address physical-world problems. The firm combines investing with hands-on support for product development, finding customers, building teams and expansion. Its European roots and global outlook include a Greece-focused sustainability and environmental-impact fund supported through EIF’s EquiFund II programme. Its current published portfolio includes Neurosoft Bioelectronics, which develops soft implantable brain-computer interfaces.

Socure operates in Cybersecurity.

A venture capital firm investing in technology companies from seed stage through growth, including AI, software, robotics, fintech and enterprise infrastructure. It provides founders with recruiting, fundraising, go-to-market and technical support.

South Park Commons is a community and venture capital firm for technical founders and researchers developing new companies. Its residency helps members explore ideas, find collaborators and decide what to build. Its funds invest from the earliest stages, including frontier AI, developer infrastructure, deep technology, healthcare and other software markets.

Crypto & Web3 company.

PsyMed Ventures backs early-stage companies developing technologies for brain health, mental health and human augmentation. Its strategy spans brain–computer interfaces and neuromodulation, precision neuroscience, AI-enabled care, digital therapeutics, neuropsychiatric drug development and genetic, RNA and cell therapies. The firm seeks human-first evidence and teams combining technical expertise with clinical understanding. It supports founders through its research community, Business Trip podcast and Future Neuro Founders workshops. PsyMed evolved from an AngelList syndicate into venture funds; its November 2025 update confirms deployment from Fund II. The legal adviser is PsyMed Ventures Management LLC, an SEC exempt reporting adviser, with distinct fund general-partner entities.

Cislunar spacecraft company.

Early-stage venture firm backing highly technical teams building differentiated and defensible software and hardware.

Meridian Street Capital is an early-stage venture firm specializing in healthcare and technology. It supports founders from inception and invests in a concentrated portfolio of businesses improving clinical delivery, patient access and healthcare infrastructure. The current official portfolio includes healthcare AI and data platforms, clinical decision support, dementia care, behavioral health and AI-enabled administrative software, including ClosedLoop.ai, Imvaria, Isaac Health, PreemptiveAI, Resonate AI, Anatomy and CloudCruise. Portfolio affiliation establishes investment relevance, but an undated card does not identify a particular cash round or ticket. The own legal notice identifies Meridian Street Capital, LLC and its official website msc.vc. The March12,2026 Form ADV identifies the same legal adviser, CRD313459 / SEC802-121134, reporting as an exempt reporting adviser. It is not represented as a fully SEC-registered investment adviser merely because commercial directories use that label. The filing gives the principal office at489 Fifth Avenue, Suite29B, NewYork, NY10017. This healthcare manager is distinct from Meridian Capital Group mortgage brokerage, Meridian Capital Asia, Capitol Meridian and unrelated similarly named property or mutual-fund businesses. The legacy meridianstreetcapital.com domain redirects to the current official website. The complete current public team comprises partners Scott Law and George Ribaroff, investors Brianna Yarnoff and Robel Mulugeta, finance director Matt Shiflett, executive assistant Caroline Targgart and venture partner Jimmy Comfort. The website publishes individually associated genuine photographs and exact roles, but not complete career biographies for every member. George’s self-written2020 account describes moving from clinical medicine into healthcare investing and the firm’s first investment in2015; that is distinct from an unverified precise incorporation day or a claim that he co-founded the manager. Older directories retaining Claire Elizabeth Smith or Steven Isenberg do not establish current staff status. Scott Law’s full legal fund-signing name is Thomas Scott Law Jr.; unrelated or senior-generation Zotec executives are not merged into his career. The current ADV lists four distinct Delaware venture vehicles: Meridian Street Ventures LP, Meridian Street Ventures II LLC, Meridian Street Capital III LP and Meridian Street2024 LP. Their gross asset values are not subscriptions raised or paid capital. FundIII’s latest available February2022 FormD amendment reports USD28,625,000 sold out of a USD50,000,000 offering, with USD21,375,000 remaining. This is verified cumulative subscription sales at that filing, not an asserted final close or paid-in-cash amount. The2024 vehicle’s June2024 offering notice reports zero sold against a USD60M target; later ADV gross assets do not prove a specific close. A separate Meridian Street2027 LP notice filed August21,2026 reports zero sold, zero investors and no first sale against an USD85M target. Its legal identity is included with capital and closing date unknown. No target, AUM, minimum commitment or portfolio valuation is booked as closed cash. Isaac Health’s own January29,2024 announcement confirms completion of a USD5.7M seed round co-led by Meridian and BCapital; its August14,2025 announcement identifies Meridian as a returning participant in a USD10.5M SeriesA led by FlareCapital. These exact events are linked under the existing institutional investor with individual allocations unpublished. Existing CloudCruise and NOCD records, all prior financial IDs and GeorgeRibaroff’s existing Partner role are preserved; neither a new personal check nor an assumed fund allocation is inferred.

Metavallon VC is an Athens-based early-stage venture manager investing in technology businesses with strong ties to Greece. The manager is identified by its institutional investor HDBI as Metavallon Partners Venture Capital Management S.A. (AEDAKES); the own website publishes Greek G.E.MI. registration 144560003000. Its January 2018 launch evolved from the earlier Metavallon.org accelerator, rather than treating the accelerator’s earlier activities as the launch date of this venture fund. It backs pre-seed, seed and seed-plus companies, particularly B2B and deep technology, with operational support and international networks. The current public team comprises nine people, spanning partners, investment and ecosystem roles. Konstantinos Karvounakis is explicitly on educational leave. George Kroustalakis is labelled Analyst on his card and Associate in his biography; both published labels remain qualified rather than selecting an unverified promotion date. Founding partner Alexandra Choli is separately retained with her explicit January 2018 affiliation; she is absent from the live nine-person directory and current tenure or exact departure is unverified. Published technical interests include artificial intelligence and machine learning, robotics, microelectronics, cybersecurity and health technology. Brain Gain broadens the strategy to deep technology and life sciences, including diagnostics, computational biology, therapeutic research and laboratory automation. Relevant primary portfolio examples include Cogitat’s neural-interface technology, gMendel genetic screening, Imagenomix AI computational pathology and Anacalypsis experimental Parkinson’s therapeutics. These are investment/research descriptions, not independent performance findings or drug approval claims. Fund I secured EUR32 million in the January 15, 2018 launch announcement. HDBI identifies Metavallon II A.K.E.S. (established Q2 2023, currently reported size EUR35.9 million) and Brain Gain A.K.E.S. (established Q4 2025, reported size EUR5.1 million); the manager rounds the latter to EUR5 million. Institutional establishment quarters and published sizes do not establish exact closing days or disbursed LP cash. Later secondary EUR36 million final-close and EUR6 million Brain Gain figures remain unverified against these primary sources. The manager’s reported EUR70 million-plus capital under management is not a new fund close. Typical investment ranges are policy, not company-specific cash tickets.

Invests in growing technology companies across the UK and Europe, including AI, semiconductors, quantum computing, space, enterprise software and financial technology. Its listed platform and private funds provide venture and growth capital.

Streamline your corporate travel management and expense processes in one app. Save time, gain efficiency, and reduce costs with this powerful, all-in-one solution.

Newfund invests in early-stage companies in Europe and the United States. Its HEKA strategy backs brain-health technologies, including digital therapies, AI diagnostics, neuroimaging and drug-delivery platforms, and helps European startups enter the US market.

Evergreen alternative investment firm backing founders building critical technology companies in industrial and life-science sectors. Novaterra combines long-term capital with hands-on operational support, drawing on entrepreneurs, venture builders and technical specialists. It invests early in people and scientific ideas intended to deliver broad societal impact, including biotechnology and healthcare. Its published team spans investment, engineering, operations, finance and marketing, supporting businesses as they develop products and commercial operations. Its disclosed neuroscience investments include Serenatis Bio’s OCD therapeutic development.

Lokalise operates in SaaS.

Lorimer Ventures is an operator-led venture capital firm founded in 2019 and based in Brooklyn, New York. It backs companies from inception across enterprise AI and software, industrial and physical AI, energy optimization, robotics and frontier technologies such as photonics and quantum computing. The firm combines its four co-founders and network of venture partners with operator support for recruitment, customer introductions and fundraising. Its own portfolio includes AI presentation platform Gamma, robotics provider Formic, energy software companies Amperon and Tyba, and AI infrastructure and workflow businesses. Lorimer Venture Partners Fund 1 and the parallel Lorimer Ventures Fund 2 vehicles are disclosed venture capital funds; no verified final fund-closing amounts are asserted.

Forum Ventures is an AI venture studio, accelerator and pre-seed investment firm focused on B2B software companies. It works with founders from concept and early product development through initial customers and financing, offering capital, go-to-market support, product and engineering help and founder community resources.

Early-stage venture-capital firm focused on consumer hardware and robotics.

Grove Ventures is an Israeli venture capital firm investing at pre-seed and seed in enterprise AI, AI infrastructure, deep technology and healthcare technology. Its investors and operating team support founders with strategy, company building, finance, hiring and marketing. Its portfolio spans technologies including quantum computing, semiconductors, photonics, physical AI and clinical software.

Heartcore Capital is a European venture investment manager backing technology founders from inception through Series A, often as their first institutional investor. Its venture strategy covers productivity and AI, software infrastructure, climate technology, travel and synthetic biology, with a current portfolio extending into robotics, quantum technology, space and defence. The firm supports founders with strategy, hiring and follow-on financing. Its dedicated Heartcore Web3 strategy invests in blockchain protocols and their native tokens, from private early-stage financing to liquid token investments, including decentralized physical infrastructure and financial applications. Fund V closed at EUR170 million in2024; Heartcore Capital Web3 I completed a EUR15 million first close in2023. These are separate vehicles rather than a combined corpus.

IBM Ventures is IBM’s corporate venture investment and startup partnership unit. It backs early-stage enterprise AI, hybrid-cloud infrastructure, cybersecurity and quantum-computing companies, and helps portfolio teams develop commercial relationships and products across IBM’s technical and enterprise-customer ecosystem. Its dedicated Enterprise AI Venture Fund launched in November 2023 with a $500 million corporate capital commitment.

Iaso Ventures is a Boston-based venture investment and company-building firm focused on neuroscience and the intersection of digital technology and life sciences. It backs therapeutics, drug delivery platforms, clinical development tools, AI-driven discovery and technologies for brain and behavioral health. It works with research hospitals, disease foundations and industry partners, and launched the Iaso NeuroImpact Fund with the Epilepsy Foundation in March 2024.

Icebreaker.vc is a venture capital firm backing idea-stage startups in Finland, Estonia and Sweden. It supports teams before a seed round, helping founders validate their ideas and build an investable company. The firm can provide up to EUR 1.5 million in initial financing and emphasizes direct involvement from multiple partners, founder well-being and support through early company development. Its third fund concentrates capital at the idea stage, retains a limited reserve through seed and avoids large reserves for later Series A financing. Icebreaker has supported technology founders since its launch in 2017.

E1 Ventures is a frontier-technology investment platform focused on scientific and engineering businesses, with published direct holdings across AI, computing, robotics, space, energy and biotechnology. Its own website lists Miami and Menlo Park and describes an AI-assisted research process called E/Quant; performance figures are unverified manager marketing claims and are not adopted as proven investment outcomes. The exact legal adviser is E1 Ventures LLC, CRD334661. The latest primary FormADV is datedSeptember8,2026 and labelled SEC Initial, State ERA Final, with SEC file801-137473 and principal address1300 El Camino Real Suite100 Menlo Park. This filing is distinguished from older website wording that the manager is exempt from registration; approval/effective registration status is not inferred merely from the application label. The adviser’s regulatory roster names managing member Anastasiya Levine and chief compliance officer Steven Robert Lapkoff, the latter sinceJune2026. Public investment communications name GP Ana Levine; the existing Ana record/role is preserved without creating another assumed namesake or asserting an independently verified formal first-name alias. The full website has no complete employee directory; regulatory officers and the publicly confirmed GP are source-scoped. Nigerian self-profile E1-affiliation and publication guest authors do not independently establish investment-team employment. The current ADV reports69 distinct private fund/SPV vehicles under E1 Master, E1 VC, E1 Funds and related series; fund gross asset values and aggregate regulatory AUM are not fund closes or new issuer cash. A historical FoundationI series reported fully soldUSD2,011,730 inOctober2024, with final closing day unpublished. Current neurotech series are separately identified; no particular vehicle is guessed as the subscribing legal buyer of a portfolio company. Primary lead-manager reporting names E1 as a follower in The Biological Computing Company’s actualUSD25M2026 seed round. Own portfolio statements explicitly concern direct investments and exclude fund-of-funds holdings.

Independent charitable foundation and catalytic investor/grant maker. Its investment arm is the EQT Foundation Fund; foundation and fund attribution should remain distinct.

Elaia is a European venture capital manager that backs B2B technology companies from pre-seed through Series B. Its digital venture funds invest in software and technology businesses, while its dedicated deep-tech seed funds support research-based startups in AI, cybersecurity, semiconductors and photonics, quantum technologies, robotics, advanced materials, energy, biotechnology, digital health and medical devices. Elaia works with research institutions including PSL and Inria to help founders commercialize scientific innovation. The Elaia brand is operated by French regulated manager Elaia Partners SAS; Lazard Elaia Capital is a separate joint venture with a distinct investment team.

Global nonprofit focused on Impact on Humanity through research, convening and impact investment in startups. The institute has investment activity but is not simply a standalone venture capital firm.

FIRSTPICK is a Vilnius-based venture capital investor backing Baltic technology founders from inception and pre-seed. It is a generalist investor with a strong focus on AI-enabled software, offering initial investments of EUR100,000–500,000 and follow-on capacity up to EUR1 million. Its funds combine financing with acceleration, practical operating support and a community of founders and experienced operators, helping young companies validate their products, find customers and prepare for later funding. The regulated legal manager is UAB FIRSTPICK Management, Lithuanian company code305005965, authorised by the Bank of Lithuania since May25,2020; the FIRSTPICK brand launched in November2022. The current public team comprises seven named staff. Earlier team member Jokūbas Vaičiulis has left, confirmed by the manager’s own farewell announcement; his existing affiliation is retained as historical. The regulator identifies four FIRSTPICK limited-partnership vehicles (ACCEL FUND/SEED FUND and their second vintages) and two managed predecessor Wise Guys vehicles, without establishing identical ownership of other Startup Wise Guys funds. The first EUR20M and second EUR25M programmes are published launch sizes, not independently verified final cash closes or amounts attributable in full to each legal vehicle. ILTE’s Lithuanian March2026 announcement specifies EUR9.3M contracted public allocation (rounded to9M in the English/manager announcements); the August2026 report confirms nearly4M deployed across seven companies, not new LP fundraising. Neuroscience portfolio relationships include Samphire Neuroscience and Psylink. Current software and deeptech holdings span AI agents, biometrics, cybersecurity and robotic sorting. Investment-policy ranges and portfolio-company aggregate revenues do not establish actual investor tickets, realised returns or regulatory clearance of medical products.

Creator Fund is a London-based venture capital firm that backs scientific founders commercialising university research across Europe. It invests at pre-seed and seed in AI, biotechnology, computing infrastructure, robotics and advanced materials, often partnering with PhD researchers, professors, students and recent graduates before they leave the laboratory. Its university investment network helps identify technical discoveries and supports founders with company building, access to talent and follow-on fundraising. The firm publishes first-cheque investments of up to EUR1 million; this is an investment ticket policy rather than its fund size. Its public portfolio includes automated chemistry, semiconductor inspection, fertility therapeutics, robotic autonomy and optical data storage. Creator Fund’s website identifies FF Creator Limited as its FCA-authorised and regulated entity, FRN1032629. The public manager brand is retained separately from any unverified legal fund subscriber or general partner.

Boardy operates in AI.

Montreal early-stage investment firm deploying its own capital into biotechnology, food, longevity, AI and clean energy businesses. Its portfolio spans computational biology, therapeutic platforms and neurological drug development, alongside radiology data company Quantivly.

Marketing & Advertising company.

byFounders is an early-stage, community-supported venture platform investing in founders from the Nordic and Baltic region, described as the New Nordics. It backs pre-seed and seed technology businesses with international ambitions, including AI, deep technology, developer tools, healthcare and biotechnology. The current public platform is operated through byFounders VC Management II ApS, an alternative investment fund manager registered with the Danish Financial Supervisory Authority; historical disclosure materials separately identify byFounders VC Management ApS/Management I and the fund, feeder and collective vehicles. Those legal manager and subscriber distinctions are retained rather than treated as duplicate platform cash buyers. Its website currently publishes thirteen investment and operating staff and forty-one members of the byFounders Collective. The collective consists of founders, operators and angels who advise and support portfolio companies; membership is not staff employment, a personal investment ticket or proof that every member subscribes to each fund. Tommy Andersen is currently a Venture Partner and the own biography expressly says he no longer actively invests, superseding older founding-partner directory labels. The retained legacy Bjarne Christiansen Partner role is preserved as an unverified earlier record rather than asserted as current published staff. Own Fund I history confirms EUR100M raised. Current primary disclosures identify Fund I, II and III plus their feeder/collective structures; targets, management assets and valuation gains are not fund closes. EIFO describes the2025 Fund III first close against a EUR110M target. The fund and its legal advisor subsequently confirm a successful final close above EUR130M in2026. The exact corpus and legal closingday remain undisclosed;130M is a lower bound, not an exact amount. Corti, Lovable, Verda and other relevant portfolio companies are directly listed with initial-investment dates; exact issuer financing rounds and individual allocations require separate primary proof. Existing investor2033 and all earlier financial relationships are retained.

CDP Venture Capital SGR S.p.A. is an Italian venture-capital investment manager supporting innovative startups, SMEs and research commercialization through direct funds, funds of funds, acceleration, technology transfer and corporate venture building. Its current legal disclosure identifies Rome registration and tax/VAT number 08480100018 and AIF-manager register number59. CDP Equity owns70% and Invitalia30%; these shareholders are distinct legal organizations. The manager operates in Rome and Milan. Its public strategies cover artificial intelligence, deep technology, biotechnology, medical technology, space, quantum computing and other sectors of national interest. The Evolution (Evoluzione) Fund invests in validated or technologically advanced deeptech ventures, typically SeriesA–B, and has EUR150million in actual subscribed capital reported at year-end2025. The Artificial Intelligence fund likewise has separate subscribed capital; public allocations, targets and manager-wide assets are distinguished from company investment proceeds and cash drawn. The2025 annual report identifies EUR4.871billion of investor-subscribed capital across its managed vehicles; this is not one fund or a new company round. Current native management and fund pages supply98 unique named team members with authentic published portraits. Some older governance and brochure listings have dated terms or superseded personnel and are not automatically current. This preserved manager record (Investor2045) is the canonical full directory. A second legacy Goldi record (Investor4725) uses the same public manager name and retains its existing historical references without reassignment. Historical legal-name continuity: the manager’s own January21,2020 announcement states that Invitalia Ventures SGR was renamed CDP Venture Capital SGR S.p.A. by its shareholders. Invitalia, the national development agency, is a separate shareholder and is not substituted as the historical operating fund manager. Invitalia’s December29,2016 announcement names Empatica among completed October–December investments by Italia Venture I, managed by Invitalia Ventures SGR. This supports the same legal manager’s historical backing, without independently establishing the issuer’s exact closing day, aggregate round amount, individual ticket or lead status. Canonical full directory Investor2045 is used for one source-qualified new check; protected legacy4725 references remain preserved without alias merging.

Cambridge Angels is a UK non-profit business angel network founded in September 2001 by Robert Sansom and David Cleevely. It connects early-stage technology and healthcare companies with experienced individual investors, provides curated opportunities and supports founders through mentoring, governance and professional networks. The group identifies a focus spanning software and AI, hardware, semiconductors, sensors, biotechnology, medical devices and digital health. Its present website identifies Amy Weatherup and Robert Swann as co-chairs, a ten-person published board, four named management people and a selected public list of individual members. Charlotte Kirby is explicitly on maternity leave; former chairs and emeritus or memorial affiliations are distinguished from current management. The own-site privacy policy identifies Cambridge Angels Group Limited, company 11413268. Companies House records that active entity as a company limited by guarantee without share capital, incorporated 13 June 2018. The 2001network founding and 2018legal incorporation are different milestones. Similarly named Cambridge Angels Ltd 13710404 and dissolved Cambridge Angels Ltd 07120891 are not assumed to be aliases or merged into the group without further legal proof. The existing application record remains typed InvestmentFirm, with its description qualifying the underlying non-profit angel-network structure. Membership is invitation-only and capped at 65 individual members alongside corporate/research members. The public directory is a selected roster rather than permission to infer private members. Members make their own independent investment decisions on each opportunity: the network explicitly states that it does not pool member assets, exercise investment discretion or manage their investments. Operating costs are covered by membership fees and sponsorship; the group states it charges companies neither pitching nor carry fees. No pooled LP fund, fundraise or discretionary AUM is manufactured from aggregate member investment totals. The homepage reports support for more than 150 companies; the portfolio page separately reports cumulative investment exceedingGBP 150 million in over 120 portfolio companies. These are undated cumulative network figures with different coverage, not one closed fund or paid tickets into individual companies. Its current exact-domain portfolio explicitly lists Eye2Gene as an AI-powered ophthalmology platform. That proves a group/member investment affiliation, but does not identify subscribing members, an exact ticket, series allocation or closing day. No personal member checks are inferred from directory membership. Current and exited portfolio sources are retained separately; aggregate values are not allocated to private companies.

Tokyo-based independent venture capital firm founded in 2012 by Anri Samata that backs founders from the earliest stages and follows their companies through later financing rounds. It invests across internet software, AI, life sciences and university-originated deep technology, alongside a dedicated decarbonization strategy. ANRI supports commercialization of scientific research and provides founders with incubation space and early-stage programs. Its sixth flagship fund began operating in January 2026, targeting a final size of ¥30 billion; a separate corporate pre-seed program invests from ANRI’s own balance sheet.

Seattle-based early-stage global technology investment platform founded in 2010 by former Microsoft executive Hank Vigil. Its partners back technical founders and product teams, drawing on a distributed network to source and assess companies. Published areas of team expertise include AI, machine learning, software, hardware, industrial technology, defense, energy and media. Alongside capital, the firm provides operating advice on technology and product strategy, business models and go-to-market execution. Its portfolio spans multiple technology cycles and industries, and its legal investment partnerships are tracked separately from the manager’s overall portfolio.